MSH2 and pancreatic neoplasm: From the 16 pathogenic and 11 HiP-VUS carriers identified through systematic panel testing of pancreatic cancer cases unselected for family history, we estimate that 2.7% (95% CI: 1.4–4.4) carry a pathogenic allele of a high-risk HBOC gene (BRCA1, BRCA2, or PALB2) and 1.3% (95% CI: 0.3–2.8) of probands carry a pathogenic allele of a Lynch Syndrome (LS)-associated MMR gene (MLH1, MSH2, PMS2, or MSH6).